Research on the impact of NSCLC on caregivers' quality of life

• Research type

  Research Study

• Full title

  Caregiver Interviews to Understand the Disease Experience and Impact of Non-Small Cell Lung Cancer on Quality of Life

• IRAS ID

  164163

• Contact name

  Clive Mulatero

• Contact email

  Clive.Mulatero@leedsth.nhs.uk

• Duration of Study in the UK

  1 years, 0 months, 14 days

• Research summary

  Lung cancer is one of the leading causes of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and has a 5 year survival rate of approximately 8%. NSCLC is associated with a variety of symptoms, such as pain, breathlessness, hoarseness and coughing, which can begin prior to diagnosis and continue throughout the course of the disease adversely affecting patients’ functional status and quality of life. Additionally considerable burden is placed on the informal caregivers and families of patients with NSCLC.
  Novartis are looking to further understand the impact of advanced NSCLC and its treatment on the caregivers and families of patients suffering from this disease. In particular, this study aims to better to understand the aspects of NSCLC and its treatment which have the biggest detrimental impact on the quality of life of patients and their caregivers. This will provide an understanding of what would be most valuable from new treatments.
  Adelphi Values are working with Novartis to perform 20, 60 minute, semi-structured qualitative interviews with informal caregivers and family members of individuals with advanced NSCLC to understand their experience of support and care giving.
  This study complements work being conducted by Adelphi Values, on behalf of Novartis, in order to understanding the patient experience of advanced NSCLC through patient qualitative interviews.
  The findings from both of these studies will be used to model the burden of disease associated with advanced NSCLC in terms of symptoms, treatment side effects, quality of life, societal and economic impacts and the aspects of the disease, treatment and care which have the biggest detrimental impact on the lives of patients and their caregivers/families. This understanding will help to inform decisions on what aspects of treatment and care are important to measure when assessing the effectiveness of a new intervention and how to measure those concepts

• REC name

  North West - Greater Manchester West Research Ethics Committee

• REC reference

  14/NW/1446

• Date of REC Opinion

  12 Dec 2014

• REC opinion

  Favourable Opinion